Clinical Scorecard: Changes in T-cell Response During the Initial Phases of Alzheimer's Disease

At a Glance

Key Highlights

• Preclinical AD subjects mount CD4+ T helper cell responses towards amyloid-β peptide with type 2 T-helper profile.
• Early enrichment of CD8+ TEMRA cells in CSF and peripheral blood with pro-inflammatory gene expression in MCI.
• Potentially beneficial role of CD4+ T cells in preclinical AD and harmful involvement of CD8+ T cells in symptomatic stages.

Guideline-Based Recommendations

Diagnosis

• Use biomarkers including cerebral amyloid-β and tau PET imaging and CSF/plasma phosphorylated tau to identify preclinical AD and MCI stages.
• Employ immunophenotyping techniques such as mass cytometry (CyTOF) and single-cell RNA sequencing (scRNA-seq) to characterize adaptive immune cell populations.

Management

• Consider promoting specific CD4+ T-cell responses during preclinical AD as a potentially beneficial strategy.
• Therapeutically target pro-inflammatory CD8+ T-cell responses in MCI if proven harmful.

Monitoring & Follow-up

• Monitor frequencies and gene expression profiles of CD4+ and CD8+ T-cell subsets in blood and CSF during early AD stages.
• Assess antigen responsiveness of T cells to amyloid-β peptides longitudinally.

Risks

• Active immunization with full-length amyloid-β peptide (e.g., AN-1792) may cause adverse effects such as meningoencephalitis.
• Unclear whether CD8+ T-cell responses are beneficial or detrimental; careful evaluation needed before immunomodulatory interventions.

Patient & Prescribing Data

Individuals at preclinical AD stage and patients with MCI due to AD

Immunomodulatory approaches may differ by disease stage: enhancing CD4+ T-cell responses early and suppressing pro-inflammatory CD8+ T-cell activity in MCI.

Clinical Best Practices

• Integrate multimodal biomarker assessment with immune profiling for early AD diagnosis.
• Use high-dimensional immune assays (CyTOF, scRNA-seq) to identify T-cell subset alterations.
• Tailor immunotherapeutic strategies to disease stage and specific T-cell phenotypes.
• Exercise caution with active immunization strategies targeting amyloid-β due to potential adverse immune reactions.

References

• Skelly et al. Scientific Commentary